Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone

British Journal of Cancer
A JungwirthM Vadillo-Buenfil

Abstract

Tumour-inhibitory effects of a new antagonist of growth hormone-releasing hormone (GH-RH), MZ-4-71, were evaluated in nude mice bearing androgen-independent human prostate cancer cell lines DU-145 and PC-3 and in Copenhagen rats implanted with Dunning R-3327 AT-1 prostatic adenocarcinoma. After 6 weeks of therapy, the tumour volume in nude mice with DU-145 prostate cancers treated with 40 microg day(-1) MZ-4-71 was significantly decreased to 37 +/- 13 mm3 (P < 0.01) compared with controls that measured 194 +/- 35 mm3. A similar inhibition of tumour growth was obtained in nude mice bearing PC-3 cancers, in which the treatment with MZ-4-71 for 4 weeks diminished the tumour volume to 119 +/- 35 mm3 compared with 397 +/- 115 mm3 for control animals. Therapy with MZ-4-71 also significantly decreased weights of PC-3 and DU-145 tumours and increased tumour doubling time. Serum levels of GH and IGF-I were significantly decreased in animals treated with GH-RH antagonist. In PC-3 tumour tissue, the levels of IGF-I and IGF-II were reduced to non-detectable values after therapy with MZ-4-71. The growth of Dunning R-3327 AT-1 tumours in rats was also significantly inhibited after 3 weeks of treatment with 100 microg of MZ-4-71 day(-1) i.p. ...Continue Reading

Citations

Jan 6, 1999·Proceedings of the National Academy of Sciences of the United States of America·H Kiaris, A V Schally
Jan 5, 2002·Proceedings of the National Academy of Sciences of the United States of America·Hippokratis KiarisJozsef L Varga
Sep 13, 2003·Prostate Cancer and Prostatic Diseases·S F WinterN M Greenberg
Jun 17, 2000·Endocrine Reviews·H M KhandwalaK E Friend
Jan 19, 2000·Proceedings of the National Academy of Sciences of the United States of America·R D Kineman
Jan 23, 2003·Proceedings of the National Academy of Sciences of the United States of America·Markus LetschJozsef L Varga
Jan 31, 2007·Proceedings of the National Academy of Sciences of the United States of America·Stefan BuchholzGabor Halmos
Feb 11, 1999·The Prostate·E ReiterG Hennen
Jan 20, 1999·Proceedings of the National Academy of Sciences of the United States of America·J L VargaZ Rékási
Oct 12, 2000·The Prostate·A V SchallyZ Rekasi
Aug 21, 2002·Proceedings of the National Academy of Sciences of the United States of America·Rebeca BustoKaroly Szepeshazi
Aug 30, 2000·Proceedings of the National Academy of Sciences of the United States of America·G HalmosT Czompoly
Jun 24, 1998·Journal of the National Cancer Institute·P Cohen
Dec 28, 1999·Proceedings of the National Academy of Sciences of the United States of America·H KiarisP Armatis
Oct 6, 2001·Frontiers in Neuroendocrinology·A V SchallyG Halmos
Nov 15, 2002·Trends in Endocrinology and Metabolism : TEM·Costanzo MorettiGaetano Frajese
Mar 31, 2004·Seminars in Oncology·Lori JeromeBrian Leyland-Jones

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxia telangiectasia

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.